2,349 results match your criteria Expert Review of Neurotherapeutics[Journal]


Disease-modifying therapies for tauopathies: agents in the pipeline.

Expert Rev Neurother 2019 Apr 11. Epub 2019 Apr 11.

g Department of Neurological Sciences , Santa Maria University Hospital , Terni , Italy.

Introduction: Tauopathies are heterogeneous clinicopathological entities characterized by abnormal neuronal and/or glial inclusions of the microtubule-binding protein tau. Primary tauopathies considered to be diseases correspond to a major class of frontotemporal lobar degeneration (FTLD) neuropathology (FTLD-Tau), including several forms of frontotemporal dementia (FTD) clinical syndromes. Little progress has been made in the past 20 years in developing effective disease-modifying drugs for primary tauopathies and available symptomatic treatments have limited efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1606715DOI Listing
April 2019
2 Reads
2.834 Impact Factor

An update on thymectomy in myasthenia gravis.

Expert Rev Neurother 2019 Apr 5:1-11. Epub 2019 Apr 5.

b Fondazione Policlinico Gemelli , IRCCS , Roma , Italy.

Introduction: Myasthenia gravis (MG) is one of the best treatable autoimmune diseases. However, in most patients, treatment is necessarily long-term and related side effects are a serious burden. Thymectomy has a special place in the disease management as a non-pharmacological disease-modifying therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1600404DOI Listing
April 2019
1 Read

Stiripentol for the treatment of seizures associated with Dravet syndrome.

Authors:
Catherine Chiron

Expert Rev Neurother 2019 Apr 2;19(4):301-310. Epub 2019 Apr 2.

a Inserm NeuroDiderot , InDev , Paris , France.

Introduction: Stiripentol is an orphan drug approved for the treatment of seizures associated with Dravet syndrome (since 2007 in Europe). Therapeutic options recently grew in this rare and severe early-onset epilepsy with the approval of stiripentol and cannabidiol in 2018 in the US and the positive trials just completed with fenfluramine. Areas covered: First, the short-term efficacy of stiripentol as adjunctive therapy to clobazam and valproate, which was discovered by serendipity thanks to a basket study and then confirmed in 1998 despite the small number of samples in phase III trials. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1593142DOI Listing
April 2019
7 Reads

Taurine and GABA neurotransmitter receptors, a relationship with therapeutic potential?

Expert Rev Neurother 2019 Apr 20;19(4):289-291. Epub 2019 Mar 20.

b Departamento de Investigación , Asociación para Evitar la Ceguera en México I.A.P. Hospital Dr. Luis Sánchez Bulnes , México City , México.

Taurine is a β-amino acid present in high concentrations in different areas of the mammalian central nervous system (CNS). It participates in different physiological processes such as osmoregulation, signal transduction, antioxidant activity, trophic factor activity, modulation of calcium movements and neurotransmission. It is known that taurine is an agonist of GABA receptors, and their affinity depends of the subunits that conform this receptor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1593827DOI Listing
April 2019
3 Reads

Extended-Release Amantadine for Levodopa-Induced Dyskinesia.

Expert Rev Neurother 2019 Apr 20;19(4):293-299. Epub 2019 Mar 20.

c Department of Neurology , University of Kansas Medical Center , Kansas City , KS , USA.

Introduction: Levodopa-induced dyskinesia (LID) is a significant impediment to the long-term use of levodopa for Parkinson's disease (PD). Relatively few studies exist that have described safe and effective therapy for LID. There is thus a significant need for therapy that can control LID to allow for greater sustainability of levodopa therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1592677DOI Listing
April 2019
3 Reads

Cognitive remediation therapy of working memory in addictive disorders: An individualized, tailored, and recovery-oriented approach.

Expert Rev Neurother 2019 Apr 20;19(4):285-287. Epub 2019 Mar 20.

b Addiction Medicine, Department of Psychiatry , Lausanne University Hospital , Lausanne , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1591950DOI Listing

Traditional Ayurvedic and herbal remedies for Alzheimer's disease: from bench to bedside.

Expert Rev Neurother 2019 Mar 18:1-16. Epub 2019 Mar 18.

e Rasashastra & Bhaishajya Kalpana , All India Institute of Ayurveda , New Delhi , India.

Introduction: Alzheimer's disease (AD) is a progressive, neurodegenerative disorder prevalent worldwide among elderly populations. Owing to limited efficacy, side effects, and poor patient compliance for current rationally designed therapies, options are being searched from alternate therapies such as Indian (Ayurvedic), Chinese, or other traditional systems. Areas covered: Following a comprehensive literature search, the authors provide a review encompassing: (1) pathophysiological changes involved in AD, (2) Ayurvedic holistic approach and herbal medicines to manage dementia and AD, and (3) traditional plants and their phytoconstituents effective in AD with description of possible mechanism of action. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1596803DOI Listing
March 2019
1 Read

An Update on Myoclonus Management.

Expert Rev Neurother 2019 Apr 20;19(4):325-331. Epub 2019 Mar 20.

a NYU Langone Health , The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, A Parkinson's Foundation Center of Excellence , New York , NY , USA.

Introduction: Myoclonus is a hyperkinetic movement disorder characterized by sudden, brief, lightning-like involuntary jerks. There are many possible causes of myoclonus and both the etiology and characteristics of the myoclonus are important in securing the diagnosis and treatment. Myoclonus may be challenging to treat, as it frequently requires multiple medications for acceptable results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1592676DOI Listing
April 2019
1 Read

Dasotraline in ADHD: novel or me too drug?

Expert Rev Neurother 2019 Apr 26;19(4):311-315. Epub 2019 Mar 26.

c Department of Psychiatry and Behavioral Health , Nisonger Center, Dual Diagnosis Clinic, Ohio State University , Columbus , OH , USA.

Introduction: A 'holy grail' of treatment options for attention-deficit hyperactivity disorder (ADHD) has been an agent with low abuse potential and peak-trough clinical effects, providing sustained therapeutic benefits throughout the day. One such agent, dasotraline, a dopamine and norepinephrine reuptake inhibitor agent, was recently reviewed by the FDA. Areas covered: The authors completed a timely drug review using a PubMed literature search using words 'Dasotraline, ADHD' 'stimulant, abuse' 'atomoxetine, ADHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1593826DOI Listing
April 2019
3 Reads

Metabolism and inflammation: implications for traumatic brain injury therapeutics.

Expert Rev Neurother 2019 Mar 8;19(3):227-242. Epub 2019 Mar 8.

a Division of Neurosurgery, Department of Clinical Neurosciences , University of Cambridge , Cambridge , UK.

Introduction: Traumatic Brain Injury (TBI) is a leading cause of death and disability in young people, affecting 69 million people annually, worldwide. The initial trauma disrupts brain homeostasis resulting in metabolic dysfunction and an inflammatory cascade, which can then promote further neurodegenerative effects for months or years, as a 'secondary' injury. Effective targeting of the cerebral inflammatory system is challenging due to its complex, pleiotropic nature. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1582332DOI Listing
March 2019
4 Reads

Almotriptan: a review of 20 years' clinical experience.

Expert Rev Neurother 2019 Mar 8:1-10. Epub 2019 Mar 8.

b Global Medical Affairs , Almirall S.A , Barcelona , Spain.

Introduction: Almotriptan (ALT), a serotonin 5-HT agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of ALT was written almost 10 years ago. The current narrative review provides an overview of the experience gained with almotriptan over that time, and highlights data published in the last decade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1591951DOI Listing

Identifying risk factors for cognitive issues in multiple sclerosis.

Expert Rev Neurother 2019 Apr 14;19(4):333-347. Epub 2019 Mar 14.

a NEUROFARBA Department, Neuroscience section , University of Florence , Florence , Italy.

Introduction: Cognitive impairment (CI) in Multiple Sclerosis (MS) has progressively regained clinical and research interest and is currently recognized as a debilitating and burdensome problem for these patients. Studying risk and protecting factors that may influence the development and course of CI is currently an area of increasing interest, due to the potential for preventive strategies. Areas covered: In this narrative review the authors briefly addressed the physiopathologic basis, assessment and management of CI in MS and then focused on identifying modifiable and not modifiable risk factors for CI in MS, providing an overview of the current knowledge in the field and indicating avenues for future research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1590199DOI Listing
April 2019
2 Reads

Edaravone for the treatment of amyotrophic lateral sclerosis.

Authors:
Hiide Yoshino

Expert Rev Neurother 2019 Mar 27;19(3):185-193. Epub 2019 Feb 27.

a Department of Neurology , Yoshino Neurology Clinic , Ichikawa-city , Japan.

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive fatal disorder that affects all skeletal muscles, leading to death, mostly within 2-4 years from onset. To date, the anti-glutamatergic drug riluzole is the only drug that has been approved for the treatment of this disease; however, its efficacy is modest. Oxidative stress is considered to be involved in the pathology of ALS, and in this regard, the free radical scavenger edaravone, which was originally developed for the treatment of acute ischemic stroke, has also been developed for the treatment of ALS. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1581610DOI Listing
March 2019
17 Reads

Effect of antiplatelet pretreatment on safety and efficacy outcomes in acute ischemic stroke patients after intravenous thrombolysis: a systematic review and meta-analysis.

Expert Rev Neurother 2019 Apr 8;19(4):349-358. Epub 2019 Mar 8.

b Department of Clinical Pharmacology , Nanjing First Hospital, Nanjing Medical University , Nanjing , China.

Background: About 40% of acute ischemic stroke patients are under antiplatelet pretreatment. Previous studies have shown conflicting results on the effect of prior antiplatelet agents on post thrombolytic clinical outcomes.

Methods: A systematic search using PubMed and EMBASE databases for eligible studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1587295DOI Listing

An update on EEG in migraine.

Expert Rev Neurother 2019 Feb 26. Epub 2019 Feb 26.

a Applied Neurophysiology and Pain Unit, Basic Medical Neuroscience and Sensory System Department , Bari Aldo Moro University , Bari , Italy.

Introduction: In the past few years, brain functional analysis has provided scientific evidence supporting the neuronal basis of migraine. The role of electroencephalography (EEG) in detecting subtle dysfunctions in sensory temporal processing has been fully re-evaluated, thanks to advances in methods of quantitative analysis. However, the diagnostic value of EEG in migraine is very low, and migraine diagnosis is completely based on clinical criteria, while the utility of EEG in migraine pathophysiology has only been confirmed in more recent applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1586534DOI Listing
February 2019

Neuromodulation for the treatment of primary headache syndromes.

Expert Rev Neurother 2019 Mar 8;19(3):261-268. Epub 2019 Mar 8.

a Department of Systems Neuroscience , University Medical Center Hamburg-Eppendorf , Hamburg , Germany.

Introduction: Neuromodulation techniques play an increasing role in the treatment of primary headaches. While initially reserved for refractory cases they are now increasingly taken into consideration in earlier treatment phases and in non-refractory situations. One of the main reasons for this paradigm shift is that most neuromodulation techniques are better tolerated as compared to the majority of pharmacological approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1585243DOI Listing
March 2019
1 Read

Modification of CSF findings in multiple sclerosis in the era of rapidly expanding treatment options.

Expert Rev Neurother 2019 Mar 27;19(3):277-283. Epub 2019 Feb 27.

a Department of Neurology , University Medical Center , Göttingen , Germany.

Background: The detection of cerebrospinal fluid (CSF)-specific oligoclonal bands (OCB) as well as an elevated antibody production directed against neurotrophic viruses remain hallmark findings in multiple sclerosis (MS). In general, individual patients show a unique pattern of OCB, which is believed to persist over time. Here, the authors revisited this assumption and investigated to what extent common anti-inflammatory MS medications can alter the level of immunoglobulins produced within the CSF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1583557DOI Listing
March 2019
1 Read

Developments in depression in epilepsy: screening, diagnosis, and treatment.

Authors:
Marco Mula

Expert Rev Neurother 2019 Mar 1;19(3):269-276. Epub 2019 Mar 1.

a Institute of Medical and Biomedical Education , St George's University of London and The Atkinson Morley Regional Neuroscience Centre, St George's University Hospitals NHS Foundation Trust , London , UK.

Introduction: Depression is one of the most frequent comorbidities in epilepsy affecting between 17% and 22% of patients, but it is still underdiagnosed and undertreated. Areas covered: This paper discusses recent advances about screening, diagnosis, and treatment of depression in epilepsy taking into account the heterogeneity of clinical scenarios where depression can occur. Expert opinion: A number of screening instruments are now validated for adults with epilepsy, and their psychometric properties are discussed but the NDDI-E is the most practical and cost-effective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1585244DOI Listing
March 2019
1 Read

Objective and biological markers in bipolar spectrum presentations.

Expert Rev Neurother 2019 Mar 27;19(3):195-209. Epub 2019 Feb 27.

a Department of Psychiatry , University of British Columbia , Vancouver , BC , Canada.

Introduction: Subthreshold presentations of bipolarity (BSPs) pose a diagnostic conundrum, in terms of whether they should be conceptualized and treated similarly as traditionally defined bipolar disorders (BD). While it has been argued that BSPs are on a pathophysiologic continuum with traditionally defined BDs, there has been limited examination of biological and objective markers in these presentations to validate this assertion. Areas covered: The authors review studies examining genetic, neurobiological, cognitive and peripheral markers in BSPs, encompassing clinical and non-clinical populations with subthreshold hypo/manic symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1580145DOI Listing
March 2019
3 Reads

Iron and manganese-related CNS toxicity: mechanisms, diagnosis and treatment.

Expert Rev Neurother 2019 Mar 21;19(3):243-260. Epub 2019 Feb 21.

a Department of Molecular Pharmacology , Albert Einstein College of Medicine , Bronx , NY , USA.

Introduction: Iron (Fe) and manganese (Mn) are essential nutrients for humans. They act as cofactors for a variety of enzymes. In the central nervous system (CNS), these two metals are involved in diverse neurological activities. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1581608DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422746PMC
March 2019
14 Reads
2.834 Impact Factor

Cariprazine for the treatment of bipolar depression: a review.

Expert Rev Neurother 2019 Apr 20;19(4):317-323. Epub 2019 Feb 20.

a Mood Disorders Psychopharmacology Unit , University Health Network , Toronto , Canada.

Introduction: Depressive symptoms and episodes dominate the course of bipolar disorder. The morbidity of bipolar disorder is disproportionately mediated by depressive symptoms; economic costs of bipolar disorder are also disproportionately due to unremitting depressive symptoms. Relatively few treatment options have established unequivocal efficacy in the treatment of bipolar depression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1580571DOI Listing
April 2019
1 Read

Sensory-targeted cognitive training for schizophrenia.

Expert Rev Neurother 2019 Mar 20;19(3):211-225. Epub 2019 Feb 20.

a INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Psychiatric Disorders: from Resistance to Response Team , Lyon, F-69678 , France.

Introduction: Auditory and visual dysfunctions are key pathophysiological features of schizophrenia (Sz). Therefore, remedial interventions that directly target such impairments could potentially drive gains in higher-order cognition (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1581609DOI Listing
March 2019
3 Reads

Emerging targets and uses of neuromodulation for pain.

Expert Rev Neurother 2019 Feb 25;19(2):109-118. Epub 2019 Jan 25.

a Spaulding Neuromodulation Center, Spaulding Rehabilitation Center and Massachusetts General Hospital , Harvard Medical School , Boston , Massachusetts (MA) , USA.

Introduction: There has been great development in the testing of invasive and non-invasive neuromodulation for chronic pain. To date, it is known that central and peripheral stimulation targets, combined or not, may influence chronic pain sensation. Although most of the significant results of chronic pain studies come from motor cortex stimulation, novel targets are being explored to increase effect sizes and to induce pain relief in non-responders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1567332DOI Listing
February 2019

Imaging in the diagnosis of idiopathic inflammatory myopathies; indications and utility.

Expert Rev Neurother 2019 Feb 7;19(2):173-184. Epub 2019 Feb 7.

b School of Medicine , Notre Dame University Australia , Fremantle , Australia.

Introduction: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of muscle diseases that carry a significant morbidity and mortality risk. The utilization of imaging in the diagnostic pathway of IIM is therefore important to obtain early diagnosis and even monitor patients over time. Areas covered: Magnetic resonance imaging (MRI) has been the main imaging modality used to detect myositis but limitations include cost and accessibility, leading to delays in time to scan, and patient contraindications. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1572507DOI Listing
February 2019
18 Reads
2.834 Impact Factor

Approaching drug-induced parkinsonism from a neurohospitalist perspective.

Authors:
Jason Margolesky

Expert Rev Neurother 2019 Feb 16;19(2):93-95. Epub 2019 Jan 16.

a Department of Neurology , University of Miami Miller School of Medicine , Miami , Fl , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1569515DOI Listing
February 2019
1 Read

Erenumab for episodic migraine prophylaxis.

Expert Rev Neurother 2019 Jan 7:1-7. Epub 2019 Jan 7.

a Department of Neurology and Experimental Neurology , Charite - Universitatsmedizin , Berlin , Germany.

Introduction: This paper reviews placebo-controlled randomized double-blind studies with erenumab for the prevention of migraine. Erenumab is a fully human monoclonal antibody (mAb), which specifically blocks the calcitonin gene-related peptide (GGRP) receptor. Areas covered: This manuscript was based on articles written in English located on PubMed using the following search terms: episodic and chronic migraine, migraine prophylaxis and prevention, CGRP, CGRP receptor, CGRP receptor antagonist, erenumab, treatment failures, and trigeminal nerve. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1565996DOI Listing
January 2019
1 Read

Improvement of gait and balance by non-invasive brain stimulation: its use in rehabilitation.

Authors:
Soumya Ghosh

Expert Rev Neurother 2019 Feb 7;19(2):133-144. Epub 2019 Jan 7.

a Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science , University of Western Australia , Nedlands , Australia.

Introduction: Gait and balance impairments are common in many neurological disorders and among the elderly, are often difficult to treat, and have a significant effect on quality of life. Areas covered: Non-invasive brain stimulation (NIBS) technologies have been recognized for their therapeutic potential in various neurologic and psychiatric disorders. There is increasing interest in treatment of gait and balance impairment using newer modalities such as NIBS. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1564042DOI Listing
February 2019
17 Reads

Cortico-limbic connectivity as a possible biomarker for bipolar disorder: where are we now?

Expert Rev Neurother 2019 Feb 1;19(2):159-172. Epub 2019 Jan 1.

a Psychiatry & Clinical Psychobiology , Division of Neuroscience, Scientific Institute Ospedale San Raffaele , Milano , Italy.

Introduction: The fronto-limbic network has been suggested as a key circuitry in the pathophysiology and maintenance of bipolar disorder. In the past decade, a disrupted connectivity within prefrontal-limbic structures was identified as a promising candidate biomarker for the disorder. Areas Covered: In this review, the authors examine current literature in terms of the structural, functional and effective connectivity in bipolar disorder, integrating recent findings of imaging genetics and machine learning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1562338DOI Listing
February 2019
2 Reads

Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis.

Expert Rev Neurother 2018 Dec 27:1-13. Epub 2018 Dec 27.

a NeuroCure Clinical Research Center , Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health , Berlin , Germany.

Introduction: Multiple Sclerosis (MS) is the most common chronic autoimmune neuroinflammatory condition in young adults. It is often accompanied by optic neuritis (ON) and retinal neuro-axonal damage causing visual disturbances. Optical coherence tomography (OCT) is a sensitive non-invasive method for quantifying intraretinal layer volumes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1559051DOI Listing
December 2018
1 Read

Unusual gait disorders: a phenomenological approach and classification.

Expert Rev Neurother 2019 Feb 30;19(2):119-132. Epub 2018 Dec 30.

a Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Division of Neurology, UHN, Division of Neurology , University of Toronto , Toronto , ON , Canada.

Introduction: Gait impairment is a very common problem in clinical practice. Multiple classifications of gait disorders are available based on anatomy, etiology, pathology and phenomenology. These classifications provide a diagnostic guide but do not clearly explain the pathophysiology of some gait disorders, which can sometimes hinder the diagnostic process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1562337DOI Listing
February 2019
7 Reads

Ocrelizumab for the treatment of multiple sclerosis.

Expert Rev Neurother 2019 Feb 28;19(2):97-108. Epub 2018 Dec 28.

a Département de Neurologie , Centre Hospitalier Universitaire de Strasbourg, Avenue Moliére , 67200 Strasbourg , France.

Introduction: In the past decade, the role of B cells in the pathogenesis of multiple sclerosis (MS) is coming to the forefront. Depletion of B cells by anti-CD20 monoclonal antibodies (mAbs) has proved to decrease the activity of the relapsing-remitting MS (RRMS) and the progression of primary progressive MS (PPMS). Areas covered: In this review, the authors discuss the rationale of the depletion of B cells in RRMS and PPMS across recent studies on the role of B cells in the pathogenesis of MS; previous clinical trials with treatments targeting B cells; the mechanism of action of ocrelizumab - a second generation anti-CD20 mAb - and recent phase III clinical trials with ocrelizumab in RRMS and PPMS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1561284DOI Listing
February 2019
1 Read

Multidisciplinary care for people with Parkinson's disease: the new kids on the block!

Expert Rev Neurother 2019 Feb 9;19(2):145-157. Epub 2019 Jan 9.

a Department of Neurology, Donders Institute for Brain, Cognition and Behaviour , Radboud University Medical Center , Nijmegen , The Netherlands.

Introduction: Parkinson's disease (PD) is a chronic multisystem disorder that causes a wide variety of motor and non-motor symptoms. Over time, the progressive nature of the disease increases the risk of complications such as falls and loss of independence, having a profound impact on quality of life. The complexity and heterogeneity of symptoms therefore warrant a holistic, multidisciplinary approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1561285DOI Listing
February 2019
13 Reads

Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.

Expert Rev Neurother 2018 Dec 18:1-12. Epub 2018 Dec 18.

a Mid-Atlantic Epilepsy and Sleep Center , Bethesda , MD , USA.

Introduction: Perampanel is an antiepileptic drug approved in the USA and Europe as monotherapy and adjunctive therapy for focal onset seizures and as adjunctive therapy for generalized tonic-clonic seizures. Areas covered: This an overview of animal data, pharmacokinetics, and clinical data published on Perampanel indexed in PubMed. Expert opinion: Pharmacological studies suggest that perampanel acts via noncompetitive antagonism of the ionotropic AMPA receptor of glutamate. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1555474DOI Listing
December 2018
6 Reads

Neuromodulation - Science and Practice in Epilepsy: Vagus Nerve Stimulation, Thalamic Deep Brain Stimulation, and Responsive NeuroStimulation.

Expert Rev Neurother 2018 Dec 11:1-13. Epub 2018 Dec 11.

a Department of Neurology and Neurological Sciences , Stanford University School of Medicine , Stanford , CA , USA.

Introduction: Neuromodulation devices can be safe and effective for the treatment of drug-resistant epilepsy. A body of scientific work supports peripheral, subcortical and cortical targets, each with different fundamental methods of action. Areas covered: High-quality evidence is available for vagal nerve stimulation (VNS), deep brain stimulation (DBS), and responsive neurostimulation (RNS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1554433DOI Listing
December 2018
1 Read

Treatment of psychiatric disturbances in common hyperkinetic movement disorders.

Expert Rev Neurother 2018 Dec 1. Epub 2018 Dec 1.

b Department of Human Neurosciences , Sapienza University of Rome , Rome.

Introduction: This paper reviews studies that have assessed the treatment of psychiatric disturbances in dystonia, tic disorders, Tourette syndrome, Huntington's disease and essential tremor. Areas covered: We searched for papers in English in Pubmed using the following keywords: blepharospasm, cervical dystonia, arm dystonia, laryngeal dystonia, spasmodic dysphonia, tic disorders, Tourette syndrome, Huntington's chorea, essential tremor, depression, anxiety, obsessive compulsive disorders, attention deficit hyperactivity disorders, psychosis, apathy. Expert commentary: Although psychiatric disturbances are frequent in hyperkinetic movement disorders, few controlled studies have assessed the treatment of psychiatric disturbances in such disorders. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1555475DOI Listing
December 2018
23 Reads

An update on ketamine and its two enantiomers as rapid-acting antidepressants.

Expert Rev Neurother 2018 Dec 4:1-10. Epub 2018 Dec 4.

a Division of Clinical Neuroscience , Chiba University Center for Forensic Mental Health , Chiba , Japan.

Introduction: Depression is one of the most disabling diseases worldwide. Approximately one-third of depressed patients are treatment-resistant to the currently available antidepressants and there is a significant therapeutic time lag of weeks to months. There is a clear unmet need for rapid-acting and more efficacious treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1554434DOI Listing
December 2018
4 Reads
2.834 Impact Factor

Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis.

Expert Rev Neurother 2018 Dec 4. Epub 2018 Dec 4.

c Department of Immunology.

Introduction: The gut microbiome helps to maintain a person's healthy state while perturbations in its function often leading to the development of inflammatory diseases including multiple sclerosis (MS). Consequently, gut-commensals which restore homeostasis have the potential to become novel therapeutic options for treating MS. MS patients have presented gut microbial dysbiosis with a reduction in bacteria belonging to the Prevotella genus. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1555473DOI Listing
December 2018
20 Reads

Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives.

Expert Rev Neurother 2018 Nov 30. Epub 2018 Nov 30.

a Neuroimaging Research Unit and Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience , San Raffaele Scientific Institute, Vita-Salute San Raffaele University , Milan , Italy .

Introduction: Advances in magnetic resonance imaging (MRI) technology and analyses are improving our understanding of the pathophysiology of multiple sclerosis (MS). Due to their ability to grade the presence of irreversible tissue loss, microstructural tissue abnormalities, metabolic changes and functional plasticity, the application of these techniques is also expanding our knowledge on the efficacy and mechanisms of action of different pharmacological and rehabilitative treatments. Areas covered. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2019.1555038DOI Listing
November 2018
19 Reads

An update on diagnosis and therapy of metabolic myopathies.

Authors:
Josef Finsterer

Expert Rev Neurother 2018 Dec 27;18(12):933-943. Epub 2018 Nov 27.

a Krankenanstalt Rudolfstiftung, Messerli Institute , Veterinary University of Vienna , Vienna , Austria.

Introduction: Metabolic myopathies are a heterogeneous group of disorders characterized by inherited defects of enzymatic pathways involved in muscle fiber energetics. Diagnosing metabolic myopathies requires a thoroughly taken individual and family history, a meticulous neurologic exam, exercise tests, blood and urine tests, needle-electromyography, nerve-conduction studies, muscle biopsy, targeted genetic tests, or next-generation sequencing. There is limited evidence from the literature to guide treatment of metabolic myopathies. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2018.1550360DOI Listing
December 2018
21 Reads

Pharmacotherapy of postpartum obsessive-compulsive disorder: a systematic review.

Authors:
Verinder Sharma

Expert Rev Neurother 2018 Dec 27;18(12):925-931. Epub 2018 Nov 27.

a Department of Psychiatry , University of Western Ontario & Parkwood Institute , London , ON , Canada.

Introduction: Despite the common occurrence of obsessive-compulsive disorder (OCD) after childbirth, the role of pharmacotherapy in its management is unclear. Areas covered: This systematic review aims to determine the role of drugs in the acute and preventative treatment of postpartum OCD. Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, four electronic databases including Medline/PubMed, PsycINFO, the Cochrane Database of Systematic Reviews, and Google Scholar were searched. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2018.1549991DOI Listing
December 2018
21 Reads

Biomarkers for bipolar disorder: current status and challenges ahead.

Expert Rev Neurother 2019 Jan 28;19(1):67-81. Epub 2018 Nov 28.

a Department of Psychiatry & Behavioral Sciences , McGovern Medical School, UT Health , Houston , TX , USA.

Introduction: Bipolar disorder (BD) is a chronic psychiatric disorder marked by clinical and pathophysiological heterogeneity. There is a high expectation that personalized approaches can improve the management of patients with BD. For that, identification and validation of potential biomarkers are fundamental. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1550361DOI Listing
January 2019
20 Reads

Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies.

Expert Rev Neurother 2018 Oct 24:1-3. Epub 2018 Oct 24.

a Department of Biochemical Sciences , Sapienza University of Rome , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2019.1540932DOI Listing
October 2018
1 Read

Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment.

Expert Rev Neurother 2018 Dec 1;18(12):953-965. Epub 2018 Nov 1.

a Department of Neurology, Graduate School of Medical Sciences , Kumamoto University , Kumamoto , Japan.

Introduction: Autoimmune autonomic ganglionopathy (AAG) is an acquired immune-mediated disorder that leads to autonomic failure. The disorder is associated with autoantibodies to the ganglionic nicotinic acetylcholine receptor (gAChR). We subsequently reported that AAG is associated with an overrepresentation of psychiatric symptoms, sensory disturbance, autoimmune diseases, and endocrine disorders. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2018.1540304DOI Listing
December 2018
47 Reads

rTMS for the treatment of Alzheimer's disease: where should we be stimulating?

Expert Rev Neurother 2018 Dec 29;18(12):903-905. Epub 2018 Oct 29.

c Department of Veterans Affairs Palo Alto Health Care System , Sierra Pacific MIRECC , Palo Alto , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2018.1538792DOI Listing
December 2018
1 Read

Is deep brain stimulation therapy underutilized for movement disorders?

Expert Rev Neurother 2018 12 15;18(12):899-901. Epub 2018 Nov 15.

a Fixel Center for Neurological Disorders, Department of Neurology , University of Florida , Gainesville , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2018.1538791DOI Listing
December 2018
1 Read

Remediation of depression-related cognitive impairment: cognitive control training as treatment augmentation.

Expert Rev Neurother 2018 Dec 26;18(12):907-913. Epub 2018 Oct 26.

a Department of Experimental Clinical and Health Psychology , Ghent University , Ghent , Belgium.

Introduction: Despite several available evidence-based interventions for major depression relapse, rates remain high and relapse prevention programs are still scarce. To increase effectiveness, novel techniques that target underlying vulnerability factors may be a promising avenue. Depression is associated with impairments in executive functioning, which is in turn associated with poor psychosocial outcomes and more Repetitive Negative Thinking (RNT), a key vulnerability factor for relapse. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2018.1537783DOI Listing
December 2018
10 Reads

Thunderclap headache: an update.

Expert Rev Neurother 2018 Dec 29;18(12):915-924. Epub 2018 Oct 29.

b Faculty of Medicine , National Yang-Ming University School of Medicine , Taipei , Taiwan.

Introduction: Thunderclap headache (TCH) is an excruciating headache that reaches maximal intensity within a minute. It has numerous potential etiologies, the most concerning of which is subarachnoid hemorrhage (SAH) due to high morbidity and mortality. Thus, patients with TCH must be evaluated urgently to identify the underlying cause and initiate prompt therapy. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2018.1537782DOI Listing
December 2018
11 Reads

Rationale and patient selection for interventional therapies in Parkinson's disease.

Expert Rev Neurother 2018 11;18(11):811-823

i Parkinson's, Movement Disorders and Neurorestoration Program , National Neuroscience Institute , Riyadh , Saudi Arabia.

Introduction: Parkinson's disease (PD) is increasing in prevalence due to a growing elderly population. Although there is no cure, there are exercise therapies and medications for mild to moderate disease. For more advanced disease, infusion or surgical interventions including deep brain stimulation surgery, levodopa carbidopa intestinal gel, and subcutaneous apomorphine infusion are considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2018.1535902DOI Listing
November 2018
34 Reads

Novel technology for mobility and balance tracking in patients with multiple sclerosis: a systematic review.

Expert Rev Neurother 2018 Nov 12;18(11):887-898. Epub 2018 Oct 12.

a Department of Kinesiology and Community Health , University of Illinois at Urbana-Champaign , Urbana , IL , USA.

Introduction: Mobility and balance impairments in patients with multiple sclerosis (MS) are major factors for decreased quality of life. Novel sensing technologies have great potential to efficiently capture subtle changes in mobility and balance performance, and thus improve current practices by providing an easy-to-implement, objective, and continuous functional tracking in MS population. Areas covered: This review details the collective findings of novel technology utilization in mobility and balance tracking in patients with MS. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2018.1533816DOI Listing
November 2018
2 Reads